Cargando…

Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations

Mutant p53 proteins (mutant p53s) have oncogenic gain-of-function properties correlated with tumor grade, castration resistance, and prostate cancer (PCa) tumor recurrence. Docetaxel is a standard first-line treatment for metastatic castration-resistant PCa (mCRPC) after the failure of hormone thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiangyan, Wu, Jason Boyang, Chung, Leland W.K., Huang, Wen-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747386/ https://www.ncbi.nlm.nih.gov/pubmed/26512780

Ejemplares similares

SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer
por: Li, Xiangyan, et al.
Publicado: (2016)

Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy
por: Xue, Linyuan, et al.
Publicado: (2020)

Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer
por: Wu, Jason, et al.
Publicado: (2013)

MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells
por: Li, Xiangyan, et al.
Publicado: (2013)

The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells
por: Mansour, Mahmoud, et al.
Publicado: (2018)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
por: Yamane, Hiromichi, et al.
Publicado: (2013)

Induction of integrin α(2) in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture
por: Ziaee, Shabnam, et al.
Publicado: (2014)

SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer
por: Chen, Jiyuan, et al.
Publicado: (2020)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2023)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Undifferentiated prostate cancer treated with docetaxel
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
por: Han, Bin, et al.
Publicado: (2012)

Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells
por: Nalairndran, Geetha, et al.
Publicado: (2021)

Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics
por: Chu, Gina Chia-Yi, et al.
Publicado: (2019)

Applications of circulating tumor cells for prostate cancer
por: Cheng, Shirley, et al.
Publicado: (2016)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Key events in cancer: Dysregulation of SREBPs
por: Li, Yunkuo, et al.
Publicado: (2023)

The Anti-inflammatory Role of Endometase/Matrilysin-2 in Human Prostate Cancer Cells
por: Khamis, Zahraa I., et al.
Publicado: (2013)

Ganoderma tsugae Inhibits the SREBP-1/AR Axis Leading to Suppression of Cell Growth and Activation of Apoptosis in Prostate Cancer Cells
por: Huang, Shih-Yin, et al.
Publicado: (2018)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner
por: Moretti, Roberta M., et al.
Publicado: (2014)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA
por: Lu, W, et al.
Publicado: (2017)

The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
por: Gruber, Martina, et al.
Publicado: (2019)

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations
por: Oros Klein, Kathleen, et al.
Publicado: (2016)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

IR-780 Dye for Near-Infrared Fluorescence Imaging in Prostate Cancer
por: Yi, Xiaomin, et al.
Publicado: (2015)

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
por: Belfiglio, Maurizio, et al.
Publicado: (2011)

Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)

SAT-144 Cooperative Mechanism of SREBP-Dependent Cholesterol Synthesis Pathway and P53 on Malignant Formation in Breast Cancer
por: Nakayama, Akitoshi, et al.
Publicado: (2020)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_cvd38l8uph8lfmikurrncfd5ol